drugset / Trial / NCT03425331
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying two immunotherapy drugs as a possible treatment for advanced non-small cell lung cancer (NSCLC). The drugs involved in this study are: * Ipilimumab * Nivolumab
Timeline
- Start
- 2018-04-10
- Primary completion
- 2020-05-18
- Completion
- 2021-11-28
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual, competing studies, and lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 1 mg/kg | Intravenous |